Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion

This publication has 10 references indexed in Scilit:

• Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion
  Blood, 1992
• The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides
  Biochemistry, 1991
• Redesigning Nature's Poisons to Create Anti-Tumor Reagents
  Science, 1987
• The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies
  International Journal of Immunopharmacology, 1987
• Evidence that pinocytosis in lymphoid cells has a low capacity.
  The Journal of cell biology, 1986
• In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.
  Journal of Clinical Investigation, 1986
• Study of the plasma clearance of antibody – ricin‐A‐chain immunotoxins
  European Journal of Biochemistry, 1986
• Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins.
  The Journal of Immunology, 1985
• B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.
  The Journal of Immunology, 1983
• Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.
  Journal of Histochemistry & Cytochemistry, 1981